About Vigil Neuroscience

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Company Highlights
Year Founded

2020

icon-altEmployees

74

Location (HQ)

USA

Since Last Funding

2 months

Monthly Website Visitors

5.7K

icon-altTotal Investment Amt

$200M

Last Funding Round

Post Ipo Equity

icon-altMoM Headcount Growth

1.37%

icon-altYoY Headcount Growth

8.81%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Health Care

Biotechnology

Biotechnology Research

Therapeutics

Life Science

Pharmaceutical Manufacturing

Pharmaceuticals